Building on these premises, we systematically investigated the relationship between P16 methylation and the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib using both public datasets and cell models of P16 methylation induced by an artificial P16-specific methyltransferase (P16-Dnmt) [29]. Here, CDK4 is linked to cancer.